SIRPA and neoplasm: By combining EGFR‐targeting peptides with an anti‐SIRP‐α antibody, pBsAbs effectively block the CD47–SIRP‐α “don't eat me” signal, promote antibody‐dependent cellular phagocytosis, and enhance macrophage infiltration into tumour spheroids, highlighting their potential to improve antitumour efficacy.92